India's local rotavirus vaccine launched to combat death linked to diarrhea
A new rotavirus vaccine created under a joint public-private partnership in India has launched this week to fight the serious and often fatal diarrheal disease in young children.
India will join more than 110 countries that have introduced the inactivated polio vaccine to their calendars. Sanofi and its Indian affiliate, Shantha Biotechnics, will supply polio vaccines to the Indian government via UNICEF. The vaccines will be used in India's universal immunization program.
In a huge Bangladeshi trial, Shanchol, Shantha Biotechnics' affordable cholera vaccine, prevented almost 40% of cholera cases. When combined with increased hand-washing, the vaccine prevented 45% of cases.
Sanofi's Shantha prepared to deliver 37M doses of long-delayed pediatric vaccine
Sanofi's Indian affiliate, Shantha Biotechnics, says it's ready to deliver 37 million doses of its low-cost pediatric pentavalent vaccine, Shan5.
After rolling out its long-delayed Shan5 vaccine in November, Sanofi's Indian affiliate, Shantha Biotechnics, is ready to provide up to 37 million doses, having already started the process on Tuesday.
It's been a long road for Shan5, the low-cost pentavalent from Sanofi-owned Shantha Biotechnics. Now, after manufacturing tie-ups four years ago cost the company a $340 million contract to supply the vaccine, it's finally rolling out the product in India.
India's rotavirus vaccines market is headed for a shake-up, and Sanofi's angling to get in on the action. It got one step closer this week, with its Indian affiliate commencing Phase III clinical trials for its own investigational vaccine.
Four years after manufacturing problems cost Sanofi-owned Shantha Biotechnics a $340 million contract to supply pentavalent vaccine Shan5, the jab has rewon the World Health Organization's favor, nabbing a positive prequalification decision that opens the door for purchases by United Nations agencies.
When Sanofi bought an 80% stake in Indian vaccinemaker Shantha Biotech in 2009, the talk was of the deal accelerating growth in emerging markets.Things played out a little differently though.
An Indian high court on Friday quashed India's income tax department's claim that Sanofi owed more than $185 million in capital gains tax in relation to its 2009 buyout of Shantha Biotechnics.